carvedilol has been researched along with rotenone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Ahmed, HI; Albohy, A; Azab, SS; Kamal, RE; Menze, E | 1 |
2 other study(ies) available for carvedilol and rotenone
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Neuroprotective repositioning and anti-tau effect of carvedilol on rotenone induced neurotoxicity in rats: Insights from an insilico& in vivo anti-Parkinson's disease study.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Carvedilol; Glial Fibrillary Acidic Protein; Glycogen Synthase; Glycogen Synthase Kinase 3 beta; Neuroprotective Agents; Neurotoxicity Syndromes; Parkinson Disease; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Rats; Receptors, N-Methyl-D-Aspartate; Rotenone; Tyrosine 3-Monooxygenase | 2022 |